<?xml version="1.0" encoding="UTF-8"?>
<p id="par0125">Camostat Mesylate is a serine protease inhibitor, a drug approved in japan for use in pancreatic inflammation. It usually blocks TMPRSS2, a protease that was recently shown to be responsible for the coronavirus S protein priming, which is crucial for viral entry into target cells and for viral spread in the infected host as published by Hoffman et al., in 
 <italic>Cell</italic>, from the German Primate center [
 <xref rid="bib0145" ref-type="bibr">29</xref>]. Several clinical trials are ongoing comparing Camostat Mesylate as a single agent vs. placebo or in combination with other drugs such as Hydroxychloroquin [
 <xref rid="bib0230" ref-type="bibr">46</xref>,
 <xref rid="bib0235" ref-type="bibr">47</xref>].
</p>
